Download this file

# pmid doi year title Hugo_Symbol
1 34791836 10.1002/cam4.4422 2022 Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. BTG1
2 35401516 10.3389/fimmu.2022.842439 2022 Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. BTG1
3 35459639 10.1016/j.bpj.2022.04.023 2022 Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants. BTG1
4 35646048 10.3389/fgene.2022.878618 2022 Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. BTG1
5 35774514 10.3389/fgene.2022.827840 2022 A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma. BTG1
6 35795062 10.3389/fonc.2022.870487 2022 Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis. BTG1
7 35880434 NA 2022 Emerging role of anti-proliferative protein BTG1 and BTG2. BTG1
8 33021411 10.1080/10428194.2020.1827243 2021 Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma. BTG1
9 33777778 10.3389/fonc.2021.628807 2021 Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. BTG1
10 34599153 10.1038/s41419-021-04187-5 2021 Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma. BTG1
11 35116576 10.21037/tcr-20-2525 2021 Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database. BTG1
12 33252851 10.1002/ctm2.221 2020 Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. BTG1
13 30350856 10.1002/jcp.27407 2019 Tumor suppressors BTG1 and BTG2: Beyond growth control. BTG1
14 30854058 10.3892/ol.2019.9900 2019 Identification of B-cell translocation gene 1-controlled gene networks in diffuse large B-cell lymphoma: A study based on bioinformatics analysis. BTG1
15 26657730 10.18632/oncotarget.6519 2016 Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress. BTG1
16 27959929 10.1371/journal.pmed.1002197 2016 Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. BTG1
17 25571854 10.3892/ijmm.2014.2058 2015 B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis. BTG1
18 25710169 10.1371/journal.ppat.1004652 2015 HITS-CLIP analysis uncovers a link between the Kaposi's sarcoma-associated herpesvirus ORF57 protein and host pre-mRNA metabolism. BTG1
19 25173640 10.1007/s13277-014-2298-x 2014 Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis. BTG1
20 22343534 10.1073/pnas.1121343109 2012 Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. BTG1
21 17466295 10.1016/j.yexcr.2007.03.021 2007 Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. BTG1
22 17485552 10.1182/blood-2006-12-064865 2007 Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. BTG1
23 11920564 10.1002/1521-4141(200204)32:4<982::AID-IMMU982>3.0.CO;2-I 2002 Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays. BTG1